Evidence map›Paper›PMID 35989204›Full record

ReviewMolecular aspects of medicine2023

Discovery, classification, evolution and diversity of Siglecs.

Takashi Angata, Ajit Varki

Open access · greenAbstract readReview
In one paragraph

Review in Molecular aspects of medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
4.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 64 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Prediction of Novel Disease-Related Regions in SIGLEC-7 byInternational journal of molecular sciences · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Sialylation in the nervous system: Functions and mechanisms.The Journal of biological chemistry · 2026
    Review
  12. Article
  13. NeuO-mediated O-acetylation of uropathogenicJournal of bacteriology · 2026
    Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Siglecs: From Biomodulation to Immunotherapy.Current protein & peptide science · 2026
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Takashi AngataInstitute of Biological Chemistry, Academia Sinica, Taipei, Taiwan; Institute of Biochemical Sciences, National Taiwan University, Taipei, Taiwan. Electronic address: angata@gate.sinica.edu.tw.
Ajit VarkiDepartment of Cellular and Molecular Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, USA. Electronic address: a1varki@health.ucsd.edu.
National Taiwan University · TWUniversity of California San Diego · US

Funding

BIOSYNTHESIS AND REGULATION OF SUBSTITUTED SIALIC ACIDSR01GM032373 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VARKI, AJIT P · 1985 to 2022
$6.9M
NIGMS NIH HHS R01 GM032373
6 · The paper itself

Abstract

Immunoglobulin (Ig) superfamily proteins play diverse roles in vertebrates, including regulation of cellular responses by sensing endogenous or exogenous ligands. Siglecs are a family of glycan-recognizing proteins belonging to the Ig superfamily (i.e., I-type lectins). Siglecs are expressed on various leukocyte types and are involved in diverse aspects of immunity, including the regulation of inflammatory responses, leukocyte proliferation, host-microbe interaction, and cancer immunity. Sialoadhesin/Siglec-1, CD22/Siglec-2, and myelin-associated glycoprotein/Siglec-4 were among the first to be characterized as members of the Siglec family, and along with Siglec-15, they are relatively well-conserved among tetrapods. Conversely, CD33/Siglec-3-related Siglecs (CD33rSiglecs, so named as they show high sequence similarity with CD33/Siglec-3) are encoded in a gene cluster with many interspecies variations and even intraspecies variations within some lineages such as humans. The rapid evolution of CD33rSiglecs expressed on leukocytes involved in innate immunity likely reflects the selective pressure by pathogens that interact and possibly exploit these Siglecs. Human Siglecs have several additional unique and/or polymorphic properties as compared with closely related great apes, changes possibly related to the loss of the sialic acid Neu5Gc, another distinctly human event in sialobiology. Multiple changes in human CD33rSiglecs compared to great apes include many examples of human-specific expression in non-immune cells, coinciding with human-specific diseases involving such cell types. Some Siglec gene polymorphisms have dual consequences-beneficial in a situation but detrimental in another. The association of human Siglec gene polymorphisms with several infectious and non-infectious diseases likely reflects the ongoing competition between the host and microbial pathogens.

Indexed as

HominidaeSialic Acid Binding Immunoglobulin-like LectinsAnimalsHumansImmunity, InnateN-Acetylneuraminic AcidSialic Acid Binding Ig-like Lectin 3N-Acetylneuraminic AcidSialic Acid Binding Ig-like Lectin 3Sialic Acid Binding Immunoglobulin-like LectinsEvolutionGenetic polymorphismHost-pathogen interactionPaired receptorsSialic acidSiglec

Identifiers

PMID35989204
PMCPMC9905256
OpenAlexW4292241412

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.